Skip to main content

Specialty Pharmacy

  • FDA approves 10th indication for Humira

    SILVER SPRING, Md. — The Food and Drug Administration has approved AbbVie’s Humira (adalimumab) to treat adults with non-infectious intermediate, posterior and panuveitas, the company announced Friday. Its new indication is the 10th for the drug in the U.S. for immune-meditated diseases.
     

  • FDA approves Gilead’s hepatitis C drug Epclusa

    SILVER SPRING, Md. — The Food and Drug Administration has approved Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg), the company announced earlier this week. Epclusa is a single tablet treatment for adults with genotype 1-6 chronic hepatitis and for patients with hepatitis C genotype 2 and 4 without the need for ribavirin. The drug for 12 weeks was approved for use in patients without cirrhosis or with compensated cirrhosis and in combination with ribavirin. 
     

  • CHPA case study explores teen abuse of dextromethorphan

    WASHINGTON -- The Consumer Healthcare Products Association has published a case study regarding efforts to curb teen abuse of over-the-counter cough medicine containing dextromethorphan. 

    The paper, “Dextromethorphan: a case study on addressing abuse of a safe and effective drug,” was published in Substance Abuse Treatment, Prevention, and Policy, an open access, peer-reviewed journal that encompasses research concerning substance abuse, with a focus on policy issues.

  • Pharmasave pharmacists trained in medication therapy management

    VANCOUVER, B.C. -- Pharmasave announced that its pharmacists have been trained to be leaders in providing medication therapy management programs.

    This includes reviewing medications for appropriateness, identifying potential problems such as drug interactions, alternative therapies and contraindications and patient counselling on appropriate use. 

  • Senators, U.S. Rep introduce bill to shorten length of biologics exclusivity

    WASHINGTON — U.S. Rep. Jan Schakowsky and Sens. Sherrod Brown and John McCain on Thursday introduced a piece of legislation aimed at shortening the period of exclusivity for brand-name biologics products. The Price Relief, Innovation and Competition for Essential Drugs (PRICED) Act would amend the Public Health Service act to change the exclusivity period from 12 years to seven years. 
     

  • Biogen names McKenzie EVP pharmaceutical operations, technology

    CAMBRIDGE, Mass. — Biogen on Thursday announced named Paul McKenzie as its EVP pharmaceutical operations and technology, effective July 1.  McKenzie, who was previously the company’s SVP global biologics manufacturing and technical operations, will head the company’s asset management, technical development, supply chain operations, global manufacturing, quality and engineering. 
     

  • Meijer gets ACHC Specialty at Retail accreditation

    GRAND RAPIDS, Mich. — Meijer on Thursday announced that it had received Specialty Pharmacy at Retail accreditation from the Accreditation Commission for Specialty Healthcare (ACHC). The announcement comes less than a year after Meijer acquired specialty pharmacy and health care company Aureus Health Services. 
     

  • McKesson unveils 5 ways value-based reimbursement is trending

    NEWTON, Mass. - Executives from McKesson Health Solutions and researcher ORC International will unveil the results of a new national research study on value-based reimbursement trends, commissioned by McKesson, at an exclusive session during AHIP’s Institute 2016, the companies announce Tuesday. 
     
X
This ad will auto-close in 10 seconds